• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.47% Nasdaq Up0.39%

    Regulus Therapeutics Inc. (RGLS)

    -NasdaqGM
    17.62 Up 0.44(2.56%) 4:00PM EDT
    |After Hours : 17.77 Up 0.15 (0.86%) 4:10PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Regulus Therapeutics Inc.
    3545 John Hopkins Court
    Suite 210
    San Diego, CA 92121
    United States - Map
    Phone: 858-202-6300
    Website: http://www.regulusrx.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:81

    Business Summary 

    Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs for the treatment of various diseases in the United States. It uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. The company’s clinical stage products include RG-101, which is a GalNAc-conjugated anti-miR that targets microRNA-122 for the treatment of patients with chronic hepatitis C virus infection; and RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease. It has strategic collaborations with Biogen Idec MA Inc. for the evaluation of the use of microRNA signatures as a biomarker for human patients with multiple sclerosis; AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases, and oncology; and GSK to discover and develop microRNA therapeutics for immuno-inflammatory diseases. The company also has strategic collaboration with Sanofi for the discovery and development of microRNA therapeutics comprising miR-21 preclinical fibrosis program for the treatment of Alport syndrome and preclinical program for oncology indications; and preclinical programs targeting miR-221/222 for oncology indications. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Regulus Therapeutics Inc.

    Corporate Governance 
    Regulus Therapeutics Inc.’s ISS Governance QuickScore as of Apr 1, 2015 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 5; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Kleanthis G. Xanthopoulos Ph.D., 57
    Chief Exec. Officer, Pres, Principal Financial & Accounting Officer and Director
    964.00K0.00
    Dr. Neil W. Gibson Ph.D., 59
    Chief Scientific Officer
    465.00K0.00
    Amy Conrad ,
    Director of Investor Relations & Corp. Communications
    N/AN/A
    Mr. David L. Szekeres , 41
    Chief Bus. Officer, Gen. Counsel and Sec.
    N/AN/A
    Dr. Zachary A. Zimmerman Ph.D.,
    Director of Bus. Devel.
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.